---
title: "Lipocine Signs TLANDO Franchise License Deal With Verity Pharma"
description: "Lipocine Inc. has signed an exclusive license agreement with Verity Pharmaceuticals to market TLANDO, an FDA-approved testosterone replacement therapy, in the U.S. and potentially in Canada. Lipocine "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/106271714.md"
published_at: "2024-01-18T14:06:06.000Z"
---

# Lipocine Signs TLANDO Franchise License Deal With Verity Pharma

> Lipocine Inc. has signed an exclusive license agreement with Verity Pharmaceuticals to market TLANDO, an FDA-approved testosterone replacement therapy, in the U.S. and potentially in Canada. Lipocine will receive a payment of $2.5 million upon signing, along with a $11 million license fee. Additionally, Lipocine will receive milestone and royalty payments totaling $259 million. The company's stock is currently gaining 0.52 percent in pre-market activity.

Pharmaceutical company, Lipocine Inc. (LPCN) Thursday said that it has entered into an exclusive license agreement with Verity Pharmaceuticals where Verity Pharma will market TLANDO in the U.S. and, if approved, in Canada.

TLANDO is the first and only FDA-approved testosterone replacement therapy option for adult males that does not require dosage measurement.

According to the agreement, Lipocine will receive a payment of $2.5 million on signing the deal along with $11 million license fee. Later, $5 million will be paid by February 1, $2.5 million by January 1, 2025, and $1 million by January 1, 2026.

The company said that additionally it will receive $259 million as milestone payment and royalty payment.

In the pre-market activity, Lipocine's stock is gaining 0.52 percent, to $3.87 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [LPCN.US - Lipocine](https://longbridge.com/en/quote/LPCN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Lipocine completes Phase III enrolment for LPCN 1154 in PPD | Lipocine has completed enrolment and dosing in its Phase III trial for LPCN 1154, an oral treatment for postpartum depre | [Link](https://longbridge.com/en/news/273214646.md) |
| Lipocine Completes Phase 3 Safety Review of LPCN 1154 for Postpartum Depression | Lipocine Inc. has completed the second independent Data Safety Monitoring Board review for its Phase 3 trial of LPCN 115 | [Link](https://longbridge.com/en/news/272274000.md) |
| Lipocine Director Jeffrey Fink Resigns Effective January 1 | Lipocine Inc. announced the resignation of Jeffrey Fink from its Board of Directors, effective January 1, 2026, due to p | [Link](https://longbridge.com/en/news/269769371.md) |
| Lipocine Nears Full Enrollment in Phase 3 Trial of Oral Brexanolone for Postpartum Depression | Lipocine Inc. announced its Phase 3 trial of oral brexanolone for postpartum depression has reached 80% enrollment, with | [Link](https://longbridge.com/en/news/269867955.md) |
| Lipocine Reports Positive Interim Safety Results in Phase 3 Trial of Oral PPD Treatment | Lipocine Inc. announced positive interim safety results in its Phase 3 trial for LPCN 1154, an oral treatment for postpa | [Link](https://longbridge.com/en/news/266388095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
